JP2023516615A5 - - Google Patents
Info
- Publication number
- JP2023516615A5 JP2023516615A5 JP2022551667A JP2022551667A JP2023516615A5 JP 2023516615 A5 JP2023516615 A5 JP 2023516615A5 JP 2022551667 A JP2022551667 A JP 2022551667A JP 2022551667 A JP2022551667 A JP 2022551667A JP 2023516615 A5 JP2023516615 A5 JP 2023516615A5
- Authority
- JP
- Japan
- Prior art keywords
- shock
- treatment
- dpp3
- sequence
- providing information
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025179567A JP2026035582A (ja) | 2020-02-27 | 2025-10-24 | ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20159848 | 2020-02-27 | ||
| EP20159848.9 | 2020-02-27 | ||
| PCT/EP2021/054911 WO2021170838A1 (en) | 2020-02-27 | 2021-02-26 | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179567A Division JP2026035582A (ja) | 2020-02-27 | 2025-10-24 | ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023516615A JP2023516615A (ja) | 2023-04-20 |
| JP2023516615A5 true JP2023516615A5 (https=) | 2024-02-29 |
Family
ID=69742802
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551667A Pending JP2023516615A (ja) | 2020-02-27 | 2021-02-26 | ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ |
| JP2025179567A Pending JP2026035582A (ja) | 2020-02-27 | 2025-10-24 | ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179567A Pending JP2026035582A (ja) | 2020-02-27 | 2025-10-24 | ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230193348A1 (https=) |
| EP (1) | EP4111204A1 (https=) |
| JP (2) | JP2023516615A (https=) |
| CN (1) | CN115244401A (https=) |
| AU (1) | AU2021228207A1 (https=) |
| BR (1) | BR112022015215A2 (https=) |
| CA (1) | CA3172349A1 (https=) |
| MX (1) | MX2022010672A (https=) |
| WO (1) | WO2021170838A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230250166A1 (en) * | 2020-02-27 | 2023-08-10 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
| AU2023315168A1 (en) | 2022-07-29 | 2025-02-13 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
| AU2023313376A1 (en) | 2022-07-29 | 2025-03-06 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| WO2025248139A1 (en) | 2024-05-31 | 2025-12-04 | 4TEEN4 Pharmaceuticals GmbH | Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU2002323501C1 (en) | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
| ES2348230T3 (es) | 2002-06-07 | 2010-12-01 | Dyax Corp. | Prevención y reducción de la isquemia. |
| EP1620734A1 (en) | 2003-04-25 | 2006-02-01 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| US20070280886A1 (en) | 2004-09-09 | 2007-12-06 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr) |
| AU2005287557B2 (en) | 2004-09-21 | 2011-10-13 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| BRPI0921469B1 (pt) | 2008-11-03 | 2022-01-18 | Molecular Partners Ag | Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica |
| MX2012002428A (es) | 2009-08-27 | 2012-09-12 | Covagen Ag | Compuestos de union il-17 y usos medicos de los mismos. |
| RU2553333C2 (ru) | 2009-12-14 | 2015-06-10 | Сцил Протеинс Гмбх | Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами |
| PL2580236T3 (pl) | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Muteiny lipokaliny łez wiążące IL-4 R alfa |
| PT2780371T (pt) | 2011-11-16 | 2019-01-30 | Adrenomed Ag | Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica |
| IL283215B2 (en) * | 2011-11-16 | 2024-05-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same |
| LT3553084T (lt) | 2011-11-16 | 2023-03-10 | Adrenomed Ag | Anti-adrenomedulino (adm) antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne-ig karkasas, skirtas organų funkcijos sutrikimo arba organų nepakankamumo profilaktikai arba sumažinimui paciento, sergančio lėtine arba ūmine liga arba esančio ūminės būklės, organizme |
| EP2780370B1 (en) | 2011-11-16 | 2019-09-25 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| ES2494190T3 (es) | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo |
| DE112017002105T5 (de) * | 2016-04-21 | 2019-04-25 | Sphingotec Therapeutics Gmbh | Verfahren zur Bestimmung von DPP3 und therapeutische Verfahren |
| WO2019077082A1 (en) * | 2017-10-18 | 2019-04-25 | Adrenomed Ag | SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM) |
| KR102835427B1 (ko) * | 2017-10-25 | 2025-07-21 | 4틴4 파마슈티컬스 게엠베하 | 특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도 |
-
2021
- 2021-02-26 US US17/802,799 patent/US20230193348A1/en active Pending
- 2021-02-26 EP EP21707707.2A patent/EP4111204A1/en active Pending
- 2021-02-26 AU AU2021228207A patent/AU2021228207A1/en active Pending
- 2021-02-26 CA CA3172349A patent/CA3172349A1/en active Pending
- 2021-02-26 MX MX2022010672A patent/MX2022010672A/es unknown
- 2021-02-26 WO PCT/EP2021/054911 patent/WO2021170838A1/en not_active Ceased
- 2021-02-26 CN CN202180015815.5A patent/CN115244401A/zh active Pending
- 2021-02-26 JP JP2022551667A patent/JP2023516615A/ja active Pending
- 2021-02-26 BR BR112022015215A patent/BR112022015215A2/pt unknown
-
2025
- 2025-10-24 JP JP2025179567A patent/JP2026035582A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023516615A5 (https=) | ||
| KR102886883B1 (ko) | Dpp3을 결정하는 방법 및 치료 방법 | |
| JP2025133108A5 (https=) | ||
| CN104530234B (zh) | 检测人vegf的组合试剂、试剂盒及其使用方法 | |
| EP4021571B1 (en) | Therapy guidance and/or therapy monitoring for treatment of shock | |
| TW201200874A (en) | Aptamer and detection method for C-reactive protein | |
| JP2026035582A (ja) | ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ | |
| JP2009517670A (ja) | エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法 | |
| US20230104578A1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock | |
| CN115769076A (zh) | 感染冠状病毒的患者中的dpp3 | |
| EP4633659A1 (en) | Dpp3 inhibitor for improvement of pulmonary function in critically ill patients | |
| JP2025527173A (ja) | 敗血性ショックを有する患者におけるｄｐｐ３の増加の予測 | |
| RU2838370C1 (ru) | Dpp3 для осуществления, мониторинга и стратификации терапии nt-adm антителами у пациентов с шоком | |
| WO2007056114B1 (en) | Compositions and methods for the detection of trypanosoma cruzi infection | |
| EP4687942A1 (en) | Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline | |
| CN119604526A (zh) | 用于治疗或预防休克的抗肾上腺髓质素（ADM）抗体或抗ADM抗体片段或抗ADM非Ig支架 | |
| KR20220145898A (ko) | 쇼크 환자의 치료에 사용하기 위한 항-아드레노메둘린 (adm) 결합제 | |
| CN108226530A (zh) | 一种邻位连接技术用于定量检测Myo含量的试剂盒、制备及使用方法 | |
| NZ747387A9 (en) | Methods for determining dpp3 and therapeutic methods | |
| HK1226484B (zh) | 预测出现主要不良心脏事件的风险的方法 |